Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible for intensive therapies are offered an autologous hematopoietic cell transplant (HCT) as front-line consolidation followed...

In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion,...

In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM) grafts, which may be associated with adverse outcomes. We compared outcomes of HCT in...

The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. In this international, phase 3 trial, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy...

Oμιλητής: Καθ. Αλέξανδρος Σπυριδωνίδης, 21ο Πανελλήνιο Συνέδριο Μεταμοσχεύσεων

The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with...

Η Novartis Oncology συνεχίζοντας τη δέσμευσή της να συμβάλλει στην ιατρική εκπαίδευση και στην επιστημονική ενημέρωση των επαγγελματιών υγείας, θα θέλαμε να σας ενημερώσουμε ότι το Τμήμα Αιματολογίας της Novartis συνεχίζει θα παρέχει για τρίτη συνεχόμενη χρονιά στους επαγγελματίες υγείας τη δυνατότητα να παρακολουθήσουν μέσω διαδικτύου την εικονική συνάντηση Ειδικών με θέμα...

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas

Transplantation in lower-risk myelodysplastic syndromes Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas ​

An analysis integrating ELN 2017, NPM1 MRD and KB scores to answer the question whether to transplant or not.   Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas

Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis. Ιt was found that T cells of patients relapsing with AML after allo-HCT exhibited reduced glycolysis and interferon-γ production. Functional studies in multiple mouse models of leukemia showed that leukemia-derived lactic...

A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds...

Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas

A study using lithium for epithelial regeneration in acute GvHD was presented. Presenter:Dr Liga  Participants:Prof.Spyridonidis, Dr Tsokanas

Rates of CLABSI are the same in internal jugular vein-and subclavian vein-CVC after allogeneic HCTThe strongest risk factor for local inflammation or fever are >6 neutropenic CVC-days·Time to local inflammation is longer with CVC placed in the internal jugular vein·CVC placed in the subclavian...

Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO). Efficacy and safety of nivolumab in real-life for the treatment of R/R Hodgkin lymphoma is comparable with that reported in clinical trials.·The main reasons for nivolumab discontinuation were referral for transplantation and disease...

In a cohort of 126 allogeneic HCT recipients transplanted 1-39 years ago,62% were seropositive/seroprotected for measles before any vaccination since transplantation. The seropositivity/seroprotection was associated with myeloproliferative disorder, reduced intensity or non-myeloablative conditioning and absence of acute grade>2 graft-versus-host disease.·Our findings strongly support a systematic assessment...

Presenter: Dr Liga, Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka, Dr Bali